C
Cue Biopharma, Inc. (CUE)
NCM – Real vaqt narxi. Valyuta: USD
29.26
-2.06 (-6.58%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
29.26
-2.06 (-6.58%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Cue Biopharma, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda kasallik bilan bog'liq T-hujayralarni maqsadli tanlash va modulyatsiya qilish uchun yangi turdagi in'ektsion dorilarni ishlab chiqadi. Uning yetakchi dori vositasi nomzodi CUE-401, Teff hujayralaridan iTreglarni induksiya qilish orqali immunitet tolerligini oshirishga mo'ljallangan bifunksional oqsil, u preklinik sinovda; va CUE-501, antivirus T-hujayralari vositasida B-hujayralarni yo'q qilish orqali autoimmün kasalliklarni davolash. Kompaniya, shuningdek, HPV+ takroriy metastatik, yoki ikkinchi liniyada va undan keyingi bemorlarda bosh va bo'yinning yassi hujayrali karsinomasini monoterapiya sifatida davolash uchun 1b klinik sinovda bo'lgan CUE-101 ni ishlab chiqadi, shuningdek, bosh va bo'yinning yassi hujayrali karsinomasini birinchi liniyada, standart davolash KEYTRUDA bilan birgalikda davolash uchun 1b klinik sinovda; va WT1+ kolorektal, oshqozon, tuxumdon va oshqozon osti bezi saratoni uchun so'nggi liniyalarda takroriy metastatik monoterapiya sifatida 1b klinik sinovda bo'lgan CUE-102 ni ishlab chiqadi. Kompaniya LG Chem, Ltd. bilan CUE-101 va CUE-102 Immuno-STATs ishlab chiqish bo'yicha hamkorlik shartnomalariga ega; Ono Pharmaceutical Co., Ltd. bilan CUE-401 ni ishlab chiqish va tijoratlashtirish huquqlari bo'yicha hamkorlik va opsion shartnomasi; va Albert Einstein College of Medicine bilan litsenzion shartnoma. Kompaniya ilgari Imagen Biopharma, Inc. nomi bilan tanilgan va 2016-yil oktyabr oyida Cue Biopharma, Inc. nomiga o'zgargan. Cue Biopharma, Inc. 2014-yilda tashkil etilgan va Massachusets shtatining Boston shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Daniel G. Baker M.D., Ph.D. | Interim Chief Development Officer |
| Dr. Rodolfo Jose Chaparro Ph.D. | Co-Founder |
| Dr. Ronald D. Seidel III, Ph.D. | Co-Founder |
| Dr. Shao-Lee Lin M.D., Ph.D. | President, CEO & Director |
| Dr. Steven C. Almo Ph.D. | Co-Founder and Chairman of Scientific & Clinical Advisory Board |
| Mr. Colin G. Sandercock J.D., MSE | Senior VP, General Counsel & Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-01 | S-8 | d100051ds8.htm |
| 2026-05-01 | 8-K | d128047d8k.htm |
| 2026-04-22 | 8-K | cue-20260422.htm |
| 2026-04-13 | 8-K | cue-20260413.htm |
| 2026-04-07 | 8-K | cue-20260401.htm |
| 2026-03-27 | DEFA14A | d107324ddefa14a.htm |
| 2026-03-27 | CORRESP | filename1.htm |
| 2026-03-16 | S-3 | d87688ds3.htm |
| 2026-03-06 | PRE 14A | cue-20260306.htm |
| 2026-02-18 | 8-K | cue-20260218.htm |
| Ms. Lucinda Warren | Principal Fin & Accounting Off. and Chief Financial & Business Officer |